Cyclin-dependent kinases(CDKs) have become potential targets for treating various diseases, especially cancer. Compound i CDK9 is an excellent and selective CDK9 inhibitor, but its major limitation is the potential to...Cyclin-dependent kinases(CDKs) have become potential targets for treating various diseases, especially cancer. Compound i CDK9 is an excellent and selective CDK9 inhibitor, but its major limitation is the potential toxicity and poor understanding of the underlying mechanism. The PROTAC(proteolysis targeting chimera) degraders of bioactive molecules can significantly induce in vitro and in vivo degradation of their target protein with high selectivity and effectively reduce the dose-limiting toxicity of small molecule drugs. Therefore, we designed and synthesized the bifunctional PROTAC molecules of i CDK9, being used for identifying its previously unknown target and revealing the underlying pharmacological mechanism.The PROTAC bifunctional molecule CD-5 could selectively and significantly degrade CDK9 with low cell toxicity. Therefore, we selected CD-5 as a chemical prober in the SILAC quantitative proteomic analysis, which disclosed that CD-5 could enormously lessen the lysine acetyltransferase KAT6A. Furthermore,KAT6A degradation induced by CD-5 repressed the levels of H3K14Ac and H3K23Ac. Lastly, the streptavidin immunoprecipitation(IP) assay confirmed a direct interaction between KAT6A and i CDK9. Collectively, our results uncover that KAT6A is a potential non-kinase target of i CDK9. Notably, this study also demonstrates that the PROTAC-SILAC strategy is an alternative approach for cellular target identification of bioactive molecules.展开更多
目的分析1例SBBYSS综合征患儿的临床及分子遗传学特点,为家系的遗传咨询及产前诊断提供依据。方法应用二代测序方法对患儿进行全基因组拷贝数变异(copy number variation, CNV)及全外显子组测序分析,并用Sanger测序法进行验证及亲源分...目的分析1例SBBYSS综合征患儿的临床及分子遗传学特点,为家系的遗传咨询及产前诊断提供依据。方法应用二代测序方法对患儿进行全基因组拷贝数变异(copy number variation, CNV)及全外显子组测序分析,并用Sanger测序法进行验证及亲源分析。结果全基因组CNV检测未见明确致病变异;全外显子组测序分析结果显示患儿的KAT6B第16外显子存在c.3367_c.3370delAGAA(p.Arg1123Argfs*6)杂合移码变异,患儿父母未检测到该变异,该变异为新发变异(de novo)。结论KAT6B第16外显子c.3367_c.3370delAGAA(p.Arg1123Argfs*6)杂合移码变异可能为患儿的致病原因,测序结果为家系的遗传咨询及产前诊断提供依据。展开更多
基金supported by grants from the National Key R&D Program of China (Nos. 2018YFA0107303 and 2020YFA0908100)the National Natural Science Foundation of China (Nos. 81773600and 82102746)+1 种基金the China Postdoctoral Science Foundation (No.2021M690095)the Fundamental Research Funds for the Central Universities (No. 20720180051)。
文摘Cyclin-dependent kinases(CDKs) have become potential targets for treating various diseases, especially cancer. Compound i CDK9 is an excellent and selective CDK9 inhibitor, but its major limitation is the potential toxicity and poor understanding of the underlying mechanism. The PROTAC(proteolysis targeting chimera) degraders of bioactive molecules can significantly induce in vitro and in vivo degradation of their target protein with high selectivity and effectively reduce the dose-limiting toxicity of small molecule drugs. Therefore, we designed and synthesized the bifunctional PROTAC molecules of i CDK9, being used for identifying its previously unknown target and revealing the underlying pharmacological mechanism.The PROTAC bifunctional molecule CD-5 could selectively and significantly degrade CDK9 with low cell toxicity. Therefore, we selected CD-5 as a chemical prober in the SILAC quantitative proteomic analysis, which disclosed that CD-5 could enormously lessen the lysine acetyltransferase KAT6A. Furthermore,KAT6A degradation induced by CD-5 repressed the levels of H3K14Ac and H3K23Ac. Lastly, the streptavidin immunoprecipitation(IP) assay confirmed a direct interaction between KAT6A and i CDK9. Collectively, our results uncover that KAT6A is a potential non-kinase target of i CDK9. Notably, this study also demonstrates that the PROTAC-SILAC strategy is an alternative approach for cellular target identification of bioactive molecules.
文摘目的分析1例SBBYSS综合征患儿的临床及分子遗传学特点,为家系的遗传咨询及产前诊断提供依据。方法应用二代测序方法对患儿进行全基因组拷贝数变异(copy number variation, CNV)及全外显子组测序分析,并用Sanger测序法进行验证及亲源分析。结果全基因组CNV检测未见明确致病变异;全外显子组测序分析结果显示患儿的KAT6B第16外显子存在c.3367_c.3370delAGAA(p.Arg1123Argfs*6)杂合移码变异,患儿父母未检测到该变异,该变异为新发变异(de novo)。结论KAT6B第16外显子c.3367_c.3370delAGAA(p.Arg1123Argfs*6)杂合移码变异可能为患儿的致病原因,测序结果为家系的遗传咨询及产前诊断提供依据。
